• https://aceh.lan.go.id/wp-content/giga/
  • https://figmmg.unmsm.edu.pe/file/
  • https://figmmg.unmsm.edu.pe/files/
  • https://figmmg.unmsm.edu.pe/mail/
  • https://ppid.lamongankab.go.id/pay/
  • https://ppid.lamongankab.go.id/wp-content/giga/
  • https://rsudngimbang.lamongankab.go.id/
  • https://dasboard.lamongankab.go.id/
  • https://dpmd.bengkaliskab.go.id/plugins/
  • https://dpmd.bengkaliskab.go.id/storage/
  • https://islamedia.web.id/
  • https://fai.unuha.ac.id/disk/
  • https://fai.unuha.ac.id/post/
  • https://fai.unuha.ac.id/plugins/
  • https://fai.unuha.ac.id/draft/
  • https://fai.unuha.ac.id/giga/
  • slot gacor hari ini
  • slot pulsa
  • slot pulsa
  • nuri77
  • gemilang77
  • slot deposit pulsa
  • slot gacor hari ini
  • slot qris
  • slot luar negeri
  • slot pulsa
  • situs toto
  • situs toto
  • toto slot
  • slot pulsa tanpa potongan
  • situs toto
  • situs toto
  • slot pulsa
  • situs toto slot
  • slot deposit pulsa
  • Paulo Hoff | IDOR – Instituto D'Or de Pesquisa e Ensino

    Paulo Hoff

    Paulo Hoff

    Research

    Dr. Hoff’s research line includes the development of new therapies for the treatment of gastrointestinal tumors. He participated in the development of 2 drugs: CAPECITABINE and TAS-102.
    Keywords: colon adenocarcinoma, rectal adenocarcinoma, neuroendocrine tumors,  pancreatic tumors, gastrointestinal stromal tumors

    EDUCATION

    PhD, Medicine, University of São Paulo

    Postdoctoral Fellow, Hematology and Oncology, Texas University, MD Anderson Cancer Center

    Full professor of Oncology, University of São Paulo

    INVESTIGATION AREAS

    Oncology

    ADITIONAL INFORMATION

    AWARDS AND HONORS

    Fellow of the American Society of Clinical Oncology (2018)

    Member of the National Academy of Medicine (2017)

    Jabuti Award, Brazilian Association of Literature (2014)

    First Brazilian to be elected for the directors' board of the American Society of Clinical Oncology (2013-2018)

    MD Anderson Cancer Center Award - Professor of the year (2000)

    Selected Publications

    H.J. Schmoll, E. Van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, B. Nordlinger, C.J. van de Velde, J. Balmana, J. Regula, I.D. Nagtegaal, R.G. Beets-Tan, D. Arnold, F. Ciardiello, P. Hoff, D. Kerr, C.H. Köhne, R. Labianca, T. Price, W. Scheithauer, A. Sobrero, J. Tabernero, D. Aderka, S. Barroso, G. Bodoky, J.Y. Douillard, H. El Ghazaly, J. Gallardo, A. Garin, R. Glynne-Jones, K. Jordan, A. Meshcheryakov, D. Papamichail, P. Pfeiffer, I. Souglakos, S. Turhal, A. Cervantes. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making, Annals of Oncology, Volume 23, Issue 10, 2012, Pages 2479-2516, ISSN 0923-7534.
    doi: 10.1093/annonc/mds236

    Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001 Apr 15;19(8):2282-92.
    doi: 10.1200/JCO.2001.19.8.2282

    Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006 May 1;24(13):2065-72. PMID: 16648507
    doi: 10.1093/jnci/djx253

    Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4147-53. PMID: 16857785.
    doi: 10.1158/1078-0432.CCR-06-0038

    Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, Fagerberg J, Bruno R. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol. 2009 Sep 1;27(25):4103-8. Epub 2009 Jul 27. PMID: 19636014.
    doi: 10.1200/JCO.2008.21.0807

    More Content